Everything glistened and sparkled in fresh light. The world was as if newly created.
Seventy-eight years ago, a Swiss chemist pedaled home through the streets of Basel and inadvertently opened a door in human consciousness that science has spent decades trying to close — and is now, with great care, beginning to reopen. Albert Hofmann's accidental and then deliberate encounter with LSD in 1943 planted a seed that prohibition buried but could not kill, and today clinical researchers in Canada and beyond are harvesting what that spring afternoon first made possible. The question society is now asking is not whether these compounds work, but whether we have finally built the wisdom and the institutions to use them well.
- A mental health crisis of historic proportions is pressing researchers to revisit treatments that were abandoned not because they failed, but because they frightened a generation of policymakers.
- MDMA-assisted psychotherapy is achieving PTSD remission rates near seventy percent in Phase 3 trials — numbers that dwarf what conventional pharmaceuticals have managed for decades.
- Canadian companies and research institutions are racing to develop regulated psychedelic therapies, positioning the country as a potential global leader in a field it helped pioneer in the 1950s.
- The central tension is integration: how to bring profoundly powerful mind-altering compounds into healthcare systems built for predictable, repeatable, pill-based medicine.
- The trajectory points toward approval and cautious adoption, but the pace depends on whether regulators, insurers, and the public can move past half a century of cultural fear.
On the afternoon of April 19, 1943, Albert Hofmann swallowed a quarter milligram of LSD at his Basel laboratory bench, believing it was the smallest dose that might reproduce the strange sensations he had accidentally experienced days before. He was wrong about the dose. Within forty minutes, dizziness and visual distortions overwhelmed him, and he asked his assistant to help him bicycle home — cars being restricted under wartime rationing. The ride through Basel's streets became something hallucinatory: the world bent and wavered, his assistant seemed to float beside him, and by the time he reached his door, his own furniture had turned threatening and strange. He feared he had broken something in himself permanently.
He had not. The next morning he woke clear and whole, and when he stepped into the garden after rain, the world appeared freshly made. What Hofmann had confirmed, through deliberate self-experiment, was that LSD was a psychoactive compound of extraordinary potency. April 19 entered history as Bicycle Day — the moment an accidental laboratory discovery became intentional science.
For a time, the discovery was taken seriously. In the 1950s, Canadian researchers at Weyburn Mental Hospital in Saskatchewan studied LSD as a treatment for alcoholism and mental illness. But as the drug became a symbol of 1960s cultural rebellion, fear overtook curiosity. The United States banned it in 1968, research collapsed, and the compound vanished into decades of prohibition.
Nearly eighty years later, the door Hofmann opened is being approached again — this time with clinical precision. MDMA-assisted psychotherapy is showing PTSD remission rates approaching seventy percent in late-stage trials. Canadian companies including Numinus Wellness, Mind Cure Health, and Havn Life Sciences are developing regulated psychedelic treatments for depression, anxiety, and trauma. The framing has shifted from transcendence to therapy, from counterculture to personalized medicine.
Before his death, Hofmann wrote to Steve Jobs — who had called LSD one of the most important experiences of his life — asking him to help rehabilitate the compound's reputation. That rehabilitation now appears to be arriving through science rather than culture. The meditation centers Hofmann imagined, where people might safely explore their own minds under professional guidance, no longer seem utopian. They seem, to a society exhausted by inadequate treatments, like an overdue answer.
On a spring afternoon in 1943, a Swiss chemist named Albert Hofmann sat at his workbench in Basel, synthesizing compounds for Sandoz Laboratories. He was thirty-two years old, methodical, searching for a drug that might stimulate circulation and breathing. Five years earlier, in 1938, he had created something else entirely: lysergic acid diethylamide, LSD. He had set it aside. But in the spring of that year, he returned to it.
While handling the compound in his lab, Hofmann began to feel strange. Dizzy. Restless. He decided to leave work and go home. Once there, the world shifted. His eyes closed and he entered what he would later describe as a dreamlike state, watching for two hours as fantastic images streamed past—extraordinary shapes, kaleidoscopic colors, a visual symphony he could not have imagined. He suspected he had absorbed the chemical through his skin, accidentally dosing himself. The experience unsettled him enough that he wanted to understand it properly.
Three days later, on April 19, 1943, Hofmann made a deliberate choice. At 4:20 in the afternoon, he swallowed a quarter milligram of LSD dissolved in water—the smallest dose he thought might replicate what he had felt. Forty minutes passed. Then dizziness returned, followed by anxiety, visual distortions, a sensation of paralysis, an urge to laugh. He realized immediately that he had taken far more than he understood. The compound was extraordinarily potent. He needed to leave the laboratory.
Hofmann asked his assistant to accompany him home by bicycle. Automobiles were restricted under wartime rationing. As they pedaled through the streets of Basel, his perception fractured. Everything in his vision wavered and bent as if reflected in curved glass. He felt rooted to the spot, unable to move, yet his assistant would later tell him they had traveled very fast. By the time he arrived home, Hofmann was delirious and bewildered, his furniture transformed into grotesque and threatening shapes. He feared he had damaged himself irreparably. But when he woke the next morning, he was clear-headed and whole. Breakfast tasted extraordinary. When he stepped into the garden after a spring rain, the world seemed newly created, everything glistening and sparkling in fresh light.
Hofmann had confirmed what he suspected: LSD was a psychoactive substance of remarkable power and potency. April 19 became known as Bicycle Day—the day a chemist's accidental discovery became intentional science, the day a compound emerged from the laboratory into history.
For decades, LSD remained a tool of serious research. In the 1950s, Canadian scientists at Weyburn Mental Hospital in Saskatchewan studied it as a treatment for alcoholism and mental illness. But in the 1960s, as the drug became entangled with cultural upheaval, fear took hold. By 1968, the United States outlawed it. Research stopped. The compound disappeared into prohibition.
Now, nearly eighty years after Hofmann's bicycle ride, psychedelics are returning to medicine. Clinical trials show that MDMA-assisted psychotherapy can help nearly seventy percent of PTSD patients achieve remission. Companies across Canada—Havn Life Sciences, Mind Cure Health, Numinus Wellness—are developing psychedelic treatments for depression, anxiety, and trauma. The approach is different this time: measured, medical, focused on healing rather than transcendence. Researchers speak of personalized medicine, of proper dosing, of creating conditions where people can safely explore their own minds with professional support.
Before he died, Hofmann wrote to Steve Jobs, asking him to help transform his "problem child into a wonder child." Jobs had said that LSD was among the two or three most important things he had ever done. The smartphone in your pocket, some argue, carries traces of that discovery. Today, as mental health crises deepen and traditional treatments fail, society is looking back at what was abandoned. Hofmann's vision of meditation centers where people could safely explore psychedelics under proper guidance no longer sounds like science fiction. It sounds like necessity. The transformation he hoped for may finally be underway.
Notable Quotes
Not very many chemists would have done a biological assay of the compound again, to figure out whether or not it's good or not. So I think it happened a little bit by accident. But then it happened by accident to somebody with the type of intuition and foresight to say, 'Hey, look, let's bring this to the world.'— Dr. Ivan Casselman, chief psychedelic officer for Havn Life Sciences
I hope you will help in the transformation of my problem child into a wonder child.— Albert Hofmann, in a letter to Steve Jobs written after turning 101
The Hearth Conversation Another angle on the story
Why does Bicycle Day matter now, more than seventy years later?
Because Hofmann proved something that had to be proven twice—once by accident, once by intention. He showed that LSD was real, that it worked, that it deserved serious study. Then the world forgot. Now we're remembering, but differently. We're not chasing transcendence. We're treating trauma.
What changed between the 1950s and now?
Fear, mostly. In the fifties, researchers at Weyburn were studying LSD for alcoholism and mental illness. It was legitimate medicine. Then the culture wars happened, and the compound became a symbol of everything society feared. Prohibition followed. Now we have data. We have clinical trials showing seventy percent remission rates for PTSD. Data is harder to fear than symbols.
Hofmann seemed to understand something about the power of what he'd created.
He did. He was careful about it. He called it his "problem child" because he knew it was potent and demanded respect. He wasn't naive about it. He wanted proper conditions, proper dosing, trained guides. That's exactly what the current research is building toward.
Does it matter that it was an accident?
Profoundly. Hofmann discovered it by chance, but then he had the courage and curiosity to investigate it intentionally. Most chemists wouldn't have done that. Most would have moved on. His willingness to understand what he'd stumbled upon is what changed everything.
What does Hofmann's letter to Steve Jobs tell us?
That he understood the reach of his discovery. Jobs said LSD was among the most important things he'd ever done. Hofmann wanted to help transform the compound's reputation from dangerous drug to therapeutic tool. He was asking for help from someone who understood both the power of the substance and the power of changing how the world sees things.
Is there a risk in celebrating Bicycle Day?
Only if we celebrate recklessly. Hofmann was clear: this is serious work, not recreation. The current researchers understand that. They're building medical frameworks, not promoting drug use. The celebration is of discovery and of the possibility of healing, not of the substance itself.